Abatacept · Orencia

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Psoriatic Arthritis, Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
US
  • Prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in patients undergoing hematopoietic stem cell transplantationFDA label
  • Polyarticular Juvenile Idiopathic Arthritis ORENCIA is indicated for the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA).Outside this platform's coverageFDA label
Product first approved 2005
JP
  • Treatment of rheumatoid arthritis (for use only in patients who have not sufficiently responded to conventional treatments)
Product first approved 2010PMDA
EU
  • Rheumatoid arthritis Orencia, in combination with methotrexate, is indicated for: the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor. the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate. A reduction in the progression of joint damage and improvement of physical function have been...
Product first approved 2007EMA
CA
  • Adult Rheumatoid Arthritis (RA) ORENCIA (abatacept) is indicated in the treatment of Rheumatoid Arthritis for: 1. reducing signs and symptoms 2. inducing clinical responses ORENCIA may be also used long-term, to inhibit the progression of structural damage, and improve physical function in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs or to TNF antagonists or to both. ORENCIA may be administered by Intravenous (IV) or Subcutaneous (SC) route (see 4 DOSAGE AND ADMINISTRATION). It is expected, based on...
Product first approved 2006Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (49)
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT05428488 · University Hospital, Montpellier
2022-11-28 – 2027-11 · Rheumatoid Arthritis
What this study did
NCT05451615 · Zhejiang Provincial People's Hospital
2022-09-30 – 2024-06-30 · Abatacept, Treatment Compliance, Rheumatoid Arthritis
What this study did
NCT02504268 · Bristol-Myers Squibb
2015-09-03 – 2020-03-19 · Rheumatoid Arthritis
What this study did
NCT02722694 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2016-08 – 2017-12 · Rheumatoid Arthritis (RA)
What this study did
NCT01299961 · University of California, Los Angeles
2011-03 – 2015-02 · Rheumatoid Arthritis
What this study did
NCT01142726 · Bristol-Myers Squibb
2010-12 – 2014-10 · Rheumatoid Arthritis
What this study did
NCT01844895 · Bristol-Myers Squibb
2013-04 – 2014-07 · Rheumatoid Arthritis
What this study did
NCT01351480 · Arthritis & Rheumatic Disease Specialties Research
2011-06 – 2014-04 · Rheumatoid Arthritis
What this study did
NCT00547521 · Bristol-Myers Squibb
2007-12 – 2014-02 · Rheumatoid Arthritis (RA)
What this study did
NCT00533897 · Bristol-Myers Squibb
2007-11 – 2014-02 · Rheumatoid Arthritis
What this study did
NCT00929864 · Bristol-Myers Squibb
2009-10 – 2012-11 · Rheumatoid Arthritis
What this study did
NCT00663702 · Bristol-Myers Squibb
2008-05 – 2012-01 · Arthritis, Rheumatoid
What this study did
NCT00409838 · Bristol-Myers Squibb
2007-04 – 2011-12 · Rheumatoid Arthritis
What this study did
NCT00095173 · Bristol-Myers Squibb
2003-12 – 2011-11 · Juvenile Rheumatoid Arthritis
What this study did
NCT00767325 · Bristol-Myers Squibb
2008-12 – 2011-10 · Rheumatoid Arthritis
What this study did
NCT00484289 · Bristol-Myers Squibb
2006-12 – 2010-12 · Rheumatoid Arthritis
What this study did
NCT01173120 · Bristol-Myers Squibb
2009-11 – 2010-07 · Rheumatoid Arthritis (RA)
What this study did
NCT00420199 · Bristol-Myers Squibb
2007-05 – 2010-05 · Active Rheumatoid Arthritis
What this study did
NCT00989235 · Bristol-Myers Squibb
2007-04 – 2009-10 · Rheumatoid Arthritis
What this study did
NCT00095147 · Bristol-Myers Squibb
2005-02 – 2009-07 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT04474847 · University of Pennsylvania
2021-03-29 – 2029-12 · Giant Cell Arteritis
What this study did
NCT06654882 · Duke University
2026-01-09 – 2029-11 · Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
What this study did
NCT05335928 · Massachusetts General Hospital
2022-07-02 – 2029-10-09 · Myocarditis Acute, Cancer
What this study did
NCT05515029 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2022-08-23 – 2026-10-16 · Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia
What this study did
NCT03841357 · Duke University
2019-10-29 – 2025-01-22 · Juvenile Idiopathic Arthritis
What this study did
NCT02108860 · University of South Florida
2015-04-25 – 2023-12-20 · Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
What this study did
NCT02971683 · Bristol-Myers Squibb
2017-05-04 – 2022-08-02 · Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy, Overlap Myositis, Juvenile Myositis Above the Age of 18
What this study did
NCT03632187 · University Hospital, Brest
2018-12-13 – 2022-06-23 · Polymyalgia Rheumatica
What this study did
NCT03192969 · Bristol-Myers Squibb
2017-07-15 – 2021-11-23 · Giant Cell Arteritis
What this study did
NCT02840175 · Assistance Publique - Hôpitaux de Paris
2017-05-18 – 2020-10-01 · Juvenile Idiopathic Arthritis
What this study did
NCT02778906 · University of Erlangen-Nürnberg Medical School
2014-11 – 2019-12 · Arthralgia, Arthritis
What this study did
NCT02067910 · University Medical Center Groningen
2014-08 – 2019-08 · Sjögren's Syndrome
What this study did
NCT02915159 · Bristol-Myers Squibb
2016-12-06 – 2019-07-23 · Sjogrens Disease
What this study did
NCT01835470 · Bristol-Myers Squibb
2013-08-09 – 2018-07-30 · Juvenile Idiopathic Arthritis
What this study did
NCT01714817 · Bristol-Myers Squibb
2013-01-22 – 2018-05-30 · Lupus Nephritis
What this study did
NCT00406653 · Bristol-Myers Squibb
2006-12 – 2009-11 · Crohn's Disease
What this study did
Phase 2/3 (4)
Rheumatoid Arthritis
NCT01333878 · Orrin M Troum, M.D. and Medical Associates
2011-03 – 2014-01 · Rheumatoid Arthritis
What this study did
NCT01001832 · Bristol-Myers Squibb
2009-12 – 2012-10 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07366801 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2025-09-03 – 2028-02-03 · Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute Lymphoblastic Leukemia, Relapse
What this study did
NCT00430677 · Bristol-Myers Squibb
2007-06 – 2011-08 · Systemic Lupus Erythematosus
What this study did
Phase 2 (56)
Psoriatic Arthritis
Rheumatoid Arthritis
NCT03784261 · Shinshu University
2018-12-17 – 2024-12-16 · Rheumatoid Arthritis
What this study did
NCT04120831 · University of Erlangen-Nürnberg Medical School
2019-10-07 – 2022-12-01 · Rheumatoid Arthritis
What this study did
NCT03084419 · Cambridge University Hospitals NHS Foundation Trust
2018-06-26 – 2020-03-01 · Rheumatoid Arthritis, Interstitial Lung Disease
What this study did
NCT02027298 · The Cleveland Clinic
2013-11 – 2014-10 · Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
What this study did
NCT00124449 · Bristol-Myers Squibb
2005-02 – 2008-04 · Arthritis, Rheumatoid
What this study did
NCT00345748 · Bristol-Myers Squibb
2006-06 – 2007-11 · Rheumatoid Arthritis
What this study did
NCT00162279 · Bristol-Myers Squibb
2000-10 – 2007-02 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07616154 · St. Jude Children's Research Hospital
2026-09-10 – 2035-09 · Sickle Cell Disease
What this study did
NCT05917522 · National Institute of Allergy and Infectious Diseases (NIAID)
2023-12-07 – 2029-07 · Kidney Transplant
What this study did
NCT03929601 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2023-10-30 – 2029-03-31 · Type 1 Diabetes Mellitus
What this study did
NCT06680661 · Leland Metheny
2026-04-08 – 2028-10-31 · Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
What this study did
NCT04925375 · Children's Hospital Medical Center, Cincinnati
2021-07-14 – 2028-07 · Interstitial Lung Disease, Common Variable Immunodeficiency
What this study did
NCT06859424 · Center for International Blood and Marrow Transplant Research
2025-07-25 – 2028-06 · AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
What this study did
NCT04380740 · Boston Children's Hospital
2022-03-30 – 2028-06 · Graft Vs Host Disease
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT07238712 · St. Petersburg State Pavlov Medical University
2025-05-10 – 2027-12-10 · Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm, Atypical Chronic Myeloid Leukemia
What this study did
NCT03924401 · Emory University
2019-08-22 – 2027-03-01 · Graft Versus Host Disease
What this study did
NCT05621759 · NYU Langone Health
2022-09-07 – 2027-01-30 · Graft Vs Host Disease
What this study did
NCT04955366 · Emory University
2021-09-22 – 2026-06-10 · Renal Transplant Recipient
What this study did
NCT05742243 · Melbourne Health
2023-02-13 – 2025-09-30 · Type 1 Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT05195645 · Assistance Publique - Hôpitaux de Paris
2022-10-27 – 2025-01-28 · Myocarditis
What this study did
NCT03457142 · Roswell Park Cancer Institute
2018-09-11 – 2024-11-06 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT04872218 · Philippe Bégin
2022-03-01 – 2024-11-04 · Peanut Allergy
What this study did
NCT01743131 · Boston Children's Hospital
2013-02-01 – 2024-03-30 · Graft vs Host Disease, Malignancy
What this study did
NCT03871361 · Universitaire Ziekenhuizen KU Leuven
2019-04-01 – 2023-12-01 · Eye Diseases, Uveitis
What this study did
NCT03215927 · Rohit Aggarwal, MD
2018-01-01 – 2023-07-30 · Myositis, Interstitial Lung Disease
What this study did
NCT03680092 · Dimitrios Tzachanis, MD PhD
2019-11-26 – 2023-06-15 · GVHD, Hematologic Neoplasms
What this study did
NCT01773707 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2013-03 – 2022-12-14 · Abnormal Glucose Tolerance, Type 1 Diabetes
What this study did
NCT03411850 · Arthritis & Rheumatism Associates, P.C.
2016-05 – 2021-12 · Sjogren's Syndrome
What this study did
NCT02270957 · Oklahoma Medical Research Foundation
2014-01 – 2021-12 · Systemic Lupus Erythematosus
What this study did
NCT04472494 · Bristol-Myers Squibb
2020-10-14 – 2021-09-13 · COVID-19, SARS-CoV-2
What this study did
NCT04261023 · University of Leeds
2020-02-24 – 2021-03-15 · Inflammatory Arthritis
What this study did
NCT03669861 · Massachusetts General Hospital
2018-11-13 – 2020-11-10 · IgG4-related Disease
What this study did
NCT02592798 · Bristol-Myers Squibb
2016-03-09 – 2020-01-28 · Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
What this study did
NCT02161406 · Dinesh Khanna, MD, MS
2014-09 – 2018-10-17 · Diffuse Cutaneous Systemic Sclerosis
What this study did
NCT01999868 · National Institute of Allergy and Infectious Diseases (NIAID)
2014-03-19 – 2018-03-01 · Psoriasis
What this study did
NCT02018042 · Columbia University
2013-09 – 2017-07-31 · Alopecia Areata
What this study did
NCT01279954 · Oregon Health and Science University
2012-01 – 2017-06 · Uveitis
What this study did
NCT01917058 · Columbia University
2013-08 – 2016-08 · Alopecia Areata
What this study did
NCT00556439 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2008-12 – 2015-08 · Takayasu's Arteritis, Giant Cell Arteritis
What this study did
NCT02232880 · Vanderbilt University Medical Center
2014-08 – 2015-06 · Hypertension
What this study did
NCT01116427 · National Institute of Allergy and Infectious Diseases (NIAID)
2010-09 – 2015-02 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT00276250 · Emory University
2005-12 – 2014-12 · Type 1 Diabetes Mellitus
What this study did
NCT00774852 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-11 – 2014-06 · Lupus Nephritis, Lupus Erythematosus, Systemic
What this study did
NCT01315938 · Karolinska Institutet
2011-01 – 2013-11-28 · Polymyositis, Dermatomyositis
What this study did
NCT01012492 · Boston Children's Hospital
2009-11 – 2013-01 · AML, ALL, Undifferentiated Leukemia, Biphenotypic Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts, Refractory Anemia With Excess Blasts-1 (5-10% Blasts), Refractory Anemia With Excess Blasts-2 (10-20% Blasts), Myelodysplastic Syndrome, Unclassified, MDS Associated With Isolated Del (5q)
What this study did
NCT01314495 · Julian M. Mackay-Wiggan
2011-09 – 2012-06 · Alopecia Totalis/Universalis
What this study did
NCT00784459 · Washington University School of Medicine
2008-10 – 2012-02 · Atopic Asthma
What this study did
Phase 1/2 (16)
Rheumatoid Arthritis
Other / comorbidity
NCT07599176 · National Heart, Lung, and Blood Institute (NHLBI)
2026-07-08 – 2035-06-30 · Sickle Cell Disease, Beta-thalassemia
What this study did
NCT05289167 · Northwell Health
2022-03-13 – 2028-08 · Graft-versus-host Disease
What this study did
NCT06145282 · National Heart, Lung, and Blood Institute (NHLBI)
2023-12-28 – 2027-11-26 · Sickle Cell Disease
What this study did
NCT05426252 · The Hospital for Sick Children
2022-03-22 – 2026-12-31 · Thalassemia in Children
What this study did
NCT04686929 · The First Affiliated Hospital of Soochow University
2021-06-01 – 2026-01-31 · Abatacept, Acute-graft-versus-host Disease, Haplo-identical HCT, Prevention
What this study did
NCT06279494 · Peking University People's Hospital
2024-03 – 2025-03 · Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia
What this study did
NCT04503616 · NYU Langone Health
2020-09-16 – 2024-08-15 · Graft-versus-host Disease
What this study did
NCT01954979 · Beth Israel Deaconess Medical Center
2014-03-27 – 2024-01-16 · Chronic Graft Versus Host Disease
What this study did
NCT03733067 · National Institute of Allergy and Infectious Diseases (NIAID)
2023-11-30 – 2023-11-30 · CTLA4 Haploinsufficency, Chronic Cytopenia
What this study did
NCT04477642 · Beth Israel Deaconess Medical Center
2020-08 – 2020-12 · COVID-19
What this study did
NCT02429934 · University of California, Los Angeles
2015-10 – 2019-09-01 · Systemic Lupus Erythematosus Arthritis
What this study did
NCT00886795 · Johns Hopkins University
2009-05 – 2013-03 · Urticaria
What this study did
NCT00468208 · University of Pennsylvania
2008-02 – 2011-08 · Wegener's Granulomatosis
What this study did
NCT00442611 · Stanford University
2008-11 – 2011-06 · Scleroderma, Diffuse, Scleroderma, Systemic
What this study did
Phase 1 (28)
Rheumatoid Arthritis
NCT06929039 · Kashiv BioSciences, LLC
2024-07-04 – 2025-02-25 · Rheumatoid Arthritis (RA
What this study did
NCT03714022 · Bristol-Myers Squibb
2018-11-09 – 2019-04-02 · Rheumatoid Arthritis
What this study did
NCT02805010 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2016-10 – 2017-02 · Rheumatoid Arthritis (RA)
What this study did
NCT01890473 · Bristol-Myers Squibb
2013-07 – 2014-11 · Rheumatoid Arthritis
What this study did
NCT01221636 · Bristol-Myers Squibb
2010-10 – 2011-02 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT06731504 · Duke University
2025-11-12 – 2028-07 · Hematologic Malignancy
What this study did
NCT07388563 · National Cancer Institute (NCI)
2026-03-26 – 2027-12-31 · Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma
What this study did
NCT06008808 · Washington University School of Medicine
2024-05-07 – 2027-11-27 · Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
What this study did
NCT04344873 · University of Utah
2025-09-01 – 2026-11-01 · Cardiovascular Diseases, Inflammation, Aging
What this study did
NCT06395038 · The Methodist Hospital Research Institute
2024-05-06 – 2026-04-30 · Frontotemporal Degeneration
What this study did
NCT05975450 · Idelberto Badell
2023-08-02 – 2025-02-14 · Kidney Transplant Recipient
What this study did
NCT04118153 · Sandra Lord, MD
2021-03-05 – 2024-05-24 · Type 1 Diabetes
What this study did
NCT06307301 · The Methodist Hospital Research Institute
2021-10-28 – 2023-12-31 · Amyotrophic Lateral Sclerosis
What this study did
NCT02867800 · Monica Bhatia
2016-07 – 2023-12-30 · Sickle Cell Disease, Graft Versus Host Disease
What this study did
NCT05981976 · Bristol-Myers Squibb
2023-08-18 – 2023-12-14 · Healthy Participants
What this study did
NCT04946669 · The First Affiliated Hospital with Nanjing Medical University
2021-02-01 – 2022-07-31 · Dermatomyositis, Abatacept
What this study did
NCT04203875 · Stuart Knechtle, M.D.
2020-03-09 – 2020-07-23 · Autoimmune Hepatitis
What this study did
NCT01917708 · Emory University
2014-01 – 2019-09-19 · Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Shwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia, Thalassemia Major, Hemophagocytic Lymphohistiocytosis, Sickle Cell Disease
What this study did
NCT03059888 · Johns Hopkins University
2017-04-12 – 2019-07-15 · Myasthenia Gravis
What this study did
NCT01693640 · NYU Langone Health
2012-06 – 2018-12-28 · Female Patients With Behcet's Syndrome
What this study did
NCT02281058 · Brigham and Women's Hospital
2015-01 – 2018-05 · Vitiligo
What this study did
NCT01272856 · Benaroya Research Institute
2011-01 – 2012-05 · Relapsing Polychondritis
What this study did
NCT00705367 · Bristol-Myers Squibb
2008-08 – 2011-07 · Lupus Nephritis
What this study did
NCT00277199 · Bristol-Myers Squibb
2002-09 – 2002-12 · Healthy Subjects
What this study did
NCT00306878 · Bristol-Myers Squibb
1995-08 – 1997-05 · Psoriasis Vulgaris
What this study did
Phase 4 (25)
Psoriatic Arthritis
NCT04106804 · University of Erlangen-Nürnberg Medical School
2018-06-06 – 2022-08 · Evaluate Bone Changes in Patients With PsA
What this study did
Rheumatoid Arthritis
NCT03227419 · Lille Catholic University
2018-01-22 – 2026-01-29 · Arthritis, Rheumatoid
What this study did
NCT03669367 · Fundacion Clinic per a la Recerca Biomédica
2019-06-03 – 2024-09-30 · Palindromic Rheumatism, Wrist
What this study did
NCT05080218 · Jeffrey Curtis
2021-11-15 – 2024-05-28 · Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
What this study did
NCT01491815 · Karolinska Institutet
2012-12-14 – 2023-12 · Rheumatoid Arthritis
What this study did
NCT02466581 · Karolinska Institutet
2015-02-03 – 2023-12 · Rheumatoid Arthritis
What this study did
NCT03882008 · University of Washington
2019-05-23 – 2023-06-30 · Rheumatoid Arthritis
What this study did
NCT04255134 · St George's, University of London
2020-09-07 – 2022-10-26 · Rheumatoid Arthritis
What this study did
NCT03492658 · Leiden University Medical Center
2018-05-17 – 2022-04-06 · Rheumatoid Arthritis, Rheumatic Diseases
What this study did
NCT03652961 · NYU Langone Health
2019-06-02 – 2021-09-27 · Rheumatoid Arthritis
What this study did
NCT03619876 · Columbia University
2019-07-10 – 2021-09-15 · Rheumatoid Arthritis, Myocardial Inflammation
What this study did
NCT01602302 · Medical University of Graz
2012-06 – 2020-11-19 · Rheumatoid Arthritis
What this study did
NCT03737708 · Astellas Pharma Korea, Inc.
2019-02-13 – 2020-06-16 · Rheumatoid Arthritis (RA)
What this study did
NCT01557374 · Assistance Publique - Hôpitaux de Paris
2012-04 – 2019-11-08 · Rheumatoid Arthritis
What this study did
NCT02652273 · NHS Greater Glasgow and Clyde
2016-01 – 2019-01 · Arthritis, Rheumatoid
What this study did
NCT02353780 · Dr. Larry W. Moreland
2015-03 – 2018-11-30 · Rheumatoid Arthritis (RA)
What this study did
NCT01638715 · Medical University of Vienna
2012-05 – 2018-08-01 · Rheumatoid Arthritis
What this study did
NCT01758198 · Bristol-Myers Squibb
2013-04-11 – 2016-12-26 · Rheumatoid Arthritis
What this study did
NCT01295151 · Julia Brown
2011-08 – 2015-11 · Rheumatoid Arthritis
What this study did
NCT01846975 · Rüdiger B. Müller
2013-05 – 2015-01 · Rheumatoid Arthritis
What this study did
NCT01717846 · University of California, Los Angeles
2012-12 – 2014-11 · Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis
What this study did
Other / comorbidity
NCT05822583 · University of Minnesota
2023-07-06 – 2025-08-11 · COVID-19
What this study did
NCT05303272 · Tongji Hospital
2021-02-01 – 2022-09-30 · Pemphigus Vulgaris
What this study did
NCT02594735 · George Washington University
2015-11 – 2021-10-22 · Dermatomyositis
What this study did
NCT02078882 · Christopher Bowlus, MD
2014-09 – 2018-10 · Primary Biliary Cirrhosis
What this study did
Early phase / not applicable (2)
Rheumatoid Arthritis
NCT02547493 · University Hospital, Montpellier
2016-03-03 – 2021-01-18 · Rheumatoid Arthritis
What this study did
NCT02053727 · University of California, Los Angeles
2014-07 – 2018-06-12 · Rheumatoid Arthritis, Chronic Hepatitis B
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Phase 2 (1)
Rheumatoid Arthritis
NCT04186871 · Bristol-Myers Squibb
2020-01-07 – 2022-12-05 · Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
What this study did
Phase 1 (3)
Rheumatoid Arthritis
NCT06126042 · Dr. Reddy's Laboratories Limited
2023-10-03 – 2024-07 · Rheumatoid Arthritis
What this study did
NCT00279734 · Bristol-Myers Squibb
2004-08 – 2005-01 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT02923583 · Momenta Pharmaceuticals, Inc.
2016-10 – 2017-07-21 · Healthy Volunteers
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 2/3 (1)
Other / comorbidity
NCT06475820 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2023-12-01 – 2027-04-01 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (2)
Rheumatoid Arthritis
NCT02557100 · Bristol-Myers Squibb
2015-11-19 – 2019-03-28 · Rheumatoid Arthritis
What this study did
NCT01000441 · University Hospital, Strasbourg, France
2009-12-23 – 2013-08-12 · Rheumatoid Arthritis
What this study did

Competitive landscape

This drug's own stage for Psoriatic Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Abatacept (Orencia): this drugApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), CD80/CD86 (B7-1/B7-2) on antigen-presenting cells, Selective T Cell Costimulation ModulatorReliable signal
NCT01860976: Proportion of ACR 20 Responders at Day 169 (Day 169): Abatacept 39.4% (95% CI 32.9 to 46) vs Placebo 22.3% (95% CI 16.7 to 27.9)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Apremilast (Otezla)ApprovedSmall moleculePDE4Reliable signal
NCT01212770: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 28.4% | Apremilast 30 mg 40.7% vs Placebo 18.3%
NCT01172938: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 30.4% | Apremilast 30 mg 38.1% vs Placebo 19%
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FReliable signal
NCT03896581: ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results).
NCT03895203: ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results).
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalNo reviewed efficacy summary in this indication
Deucravacitinib (Sotyktu)ApprovedSmall moleculeTYK2Reliable signal
NCT04908189: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002
NCT04908202: POETYK PsA-1 (NCT04908202), primary endpoint ACR20 at week 16: met, p<0.0001
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Reliable signal
NCT02376790: ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005)
NCT00317499: ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001)
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphanot yet graded
NCT02181673: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% phase 3 result · pivotal pending
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT04882098: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants
NCT03162796: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (Week 24): Guselkumab 100 mg q8w 52% | Guselkumab 100 mg q4w 59.4% vs Placebo 22.2%
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Ixekizumab (Taltz)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT02349295: ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001
NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo.
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03675308: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT04632927: HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002.
NCT02404350: ACR20 at week 16: secukinumab 300 mg load 62.6%, 150 mg load 55.5%, 150 mg no load 59.5% vs placebo 27.4%; odds ratios 4.58 (95% CI 3.16 to 6.63), 3.38 (2.35 to 4.87) and 4.02 (2.78 to 5.79), all p<0.0001 (CT.gov posted results).
Tildrakizumab (Ilumya)ApprovedMonoclonal antibodyIL-23 p19Partial signalNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3not yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03104400: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5)
NCT03104374: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 56.9% (95% CI 50.2 to 63.6) | Upadacitinib 30 mg 63.8% (95% CI 57.4 to 70.1) vs Placebo 24.1% (95% CI 18.3 to 29.8)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
NetakimabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT03598751: ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo.
SonelokimabPhase 3Antibody-derived scaffoldIL-17A/FPartial signal
NCT06641076: Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52).
NCT05640245: ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled)
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
VunakizumabPhase 3Monoclonal antibodyIL-17Partial signal
NCT05055934: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively
ZasocitinibPhase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HS-10374Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
LPX-TI641Phase 1Small moleculeTIM receptor (Treg-expanding)not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(21 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Orencia (Abatacept) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2026-11 · NCT05428488 · CT.gov ↗
What to watch
2027 (11)
January 2027 (1)
Phase 2Graft Vs Host DiseaseActive not recruiting
Est. primary completion 2027-01-30 · NCT05621759 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Graft Versus Host DiseaseActive not recruiting
Est. primary completion 2027-03-01 · NCT03924401 · CT.gov ↗
What to watch
Phase 1Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma …Recruiting
Est. primary completion 2027-03-31 · NCT07388563 · CT.gov ↗
What to watch
Phase 2Type 1 Diabetes MellitusActive not recruiting
Est. primary completion 2027-03-31 · NCT03929601 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Graft Vs Host DiseaseRecruiting
Est. primary completion 2027-05 · NCT04380740 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2/3Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute Lymphoblastic Leukemia …Recruiting
Est. primary completion 2027-06-01 · NCT07366801 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Kidney TransplantRecruiting
Est. primary completion 2027-07 · NCT05917522 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host DiseaseRecruiting
Est. primary completion 2027-09-08 · NCT06008808 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Graft-versus-host DiseaseRecruiting
Est. primary completion 2027-11 · NCT05289167 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1Hematologic MalignancyRecruiting
Est. primary completion 2027-12 · NCT06731504 · CT.gov ↗
What to watch
Phase 2Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm …Active not recruiting
Est. primary completion 2027-12-10 · NCT07238712 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome) …Recruiting
Est. primary completion 2028-06 · NCT06859424 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Interstitial Lung Disease, Common Variable ImmunodeficiencyRecruiting
Est. primary completion 2028-07 · NCT04925375 · CT.gov ↗
What to watch
2029 (3)
April 2029 (1)
Phase 3Myocarditis Acute, CancerRecruiting
Est. primary completion 2029-04-09 · NCT05335928 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Polyarticular Course Juvenile Idiopathic Arthritis (JIA)Recruiting
Est. primary completion 2029-05-30 · NCT06654882 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Giant Cell ArteritisRecruiting
Est. primary completion 2029-12 · NCT04474847 · CT.gov ↗
What to watch
2032 (1)
June 2032 (1)
Phase 1/2Sickle Cell Disease, Beta-thalassemiaRecruiting
Est. primary completion 2032-06-30 · NCT07599176 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Phase 2Sickle Cell DiseaseRecruiting
Est. primary completion 2034-09 · NCT07616154 · CT.gov ↗
What to watch

See the full readout calendar ↗